Alpha 2.0
Login Register
» Authors » Manuel Ruiz Borrego

Manuel Ruiz Borrego

Explore the profile of Manuel Ruiz Borrego including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 685
Followers 0
Related Specialties
Oncology
General Medicine
General Surgery
Top 10 Co-Authors
Antonio Llombart-Cussac
Javier Cortes
Lourdes Calvo
Cristina Saura
Jose Manuel Perez-Garcia
Miguel Martin
Sung-Bae Kim
Miguel Sampayo-Cordero
Yeon Hee Park
Peter Schmid
Published In
Lancet Oncol
Breast Cancer Res Treat
J Clin Oncol
N Engl J Med
Med Clin (Barc)
Affiliations
Soon will be listed here.
Recent Articles
1.
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Jhaveri K, Neven P, Casalnuovo M, Kim S, Tokunaga E, Aftimos P, et al.
N Engl J Med . 2024 Dec; PMID: 39660834
Background: Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα (). Methods: In a...
2.
SGLT2 inhibition improves PI3Kα inhibitor-induced hyperglycemia: findings from preclinical animal models and from patients in the BYLieve and SOLAR-1 trials
Borrego M, Lu Y, Reyes-Cosmelli F, Park Y, Yamashita T, Chiu J, et al.
Breast Cancer Res Treat . 2024 Aug; 208(1):111-121. PMID: 39177931
Purpose: Alpelisib plus fulvestrant demonstrated a significant progression-free survival benefit versus fulvestrant in patients with PIK3CA-mutated HR+ /HER2- advanced breast cancer (ABC) (SOLAR-1). Hyperglycemia, an on-target adverse effect of PI3Kα...
3.
Selecting postoperative adjuvant systemic therapy for early-stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays
Hyams D, Bareket-Samish A, Rocha J, Diaz-Botero S, Franco S, Gagliato D, et al.
J Surg Oncol . 2024 Jun; 130(2):166-187. PMID: 38932668
Gene expression assays (GEAs) can guide treatment for early-stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA....
4.
Retrospective registry of patients with locally advanced/metastatic HR/HER2 breast cancer treated in clinical practice in Andalusia
Chavarria Piudo N, Blancas I, Gonzalez Flores E, Henao Carrasco F, Lopez Alvarez P, Morales Pancorbo D, et al.
Clin Transl Oncol . 2024 Jun; 26(12):3131-3141. PMID: 38831191
Background: Limited data are available regarding the real-world effectiveness and safety of Cyclin Dependent Kinase 4/6 inhibitor (CDK4/6i) (palbociclib/ribociclib) just as a first-line treatment for patients with hormone receptor-positive/human epidermal...
5.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Fehm T, Cottone F, Dunton K, Andre F, Krop I, Park Y, et al.
Lancet Oncol . 2024 May; 25(5):614-625. PMID: 38697155
Background: In DESTINY-Breast02, patients with HER2-positive unresectable or metastatic breast cancer who received trastuzumab deruxtecan demonstrated superior progression-free and overall survival compared with those receiving treatment of physician's choice. We...
6.
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
Llombart-Cussac A, Perez-Garcia J, Borrego M, Tolosa P, Blanch S, Fernandez-Ortega A, et al.
EClinicalMedicine . 2024 Apr; 71:102520. PMID: 38638399
Background: Hyperglycaemia is an early and frequent adverse event during alpelisib treatment. METALLICA aimed to evaluate prophylactic metformin to prevent or reduce hyperglycaemia occurrence in patients with HR+/HER2-/-mutated advanced breast...
7.
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
Andre F, Park Y, Kim S, Takano T, Im S, Borges G, et al.
Lancet . 2023 Apr; 401(10390):1773-1785. PMID: 37086745
Background: In the single-arm, phase 2 DESTINY-Breast01 trial, trastuzumab deruxtecan showed robust activity in patients with HER2-positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine; a population...
8.
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain study
Perez-Garcia J, Gebhart G, Borrego M, Schmid P, Marme F, Prat A, et al.
Future Oncol . 2022 Oct; 18(33):3677-3688. PMID: 36300423
What Is This Summary About?: This is a summary of a publication about the PHERGain study, which was published in in May 2021. The study includes 376 women with a...
9.
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
Di Cosimo S, Perez-Garcia J, Bellet M, Dalenc F, Gil Gil M, Borrego M, et al.
Oncologist . 2022 Oct; 28(1):23-32. PMID: 36239405
Background: Palbociclib has gained a central role in the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Despite its manageable toxicity profile, venous...
10.
Who are the women who enrolled in the POSITIVE trial: A global study to support young hormone receptor positive breast cancer survivors desiring pregnancy
Partridge A, Niman S, Ruggeri M, Peccatori F, Azim Jr H, Colleoni M, et al.
Breast . 2021 Aug; 59:327-338. PMID: 34390999
Background: Premenopausal women with early hormone-receptor positive (HR+) breast cancer receive 5-10 years of adjuvant endocrine therapy (ET) during which pregnancy is contraindicated and fertility may wane. The POSITIVE study...